Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

BearDownAZ

Sep 02, 2018 12:42PM

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

KOO-KOO2

Sep 02, 2018 01:11PM

tada

Rank: President [?]

Points: 7698 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

in response to

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

KOO-KOO2

posted on Sep 03, 2018 12:50AM

KK2 - Zenith Epigenetics Ltd or ZCC on NASDAQ, not going to happen any time soon.

tada

3 Recommendations

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

KOO-KOO2

Sep 03, 2018 06:06AM

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

tada

Sep 03, 2018 11:22PM

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial

KOO-KOO2

Sep 04, 2018 05:52AM

Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial